Novel diabetes treatment developed in Desai Lab to power SF-area startup

An insulin-generating implant that utilizes nanotechnology developed in theDesai Lab is closer to becoming a real treatment for diabetes, after being acquired by a San Francisco-based startup.The biotechnology company Encellin acquired exclusive worldwide rights to the technology, originally developed in the laboratory ofTejal Desai, PhD, chair of theDepartment of Bioengineering and Therapeutic Sciences, a joint department of...
Source: UCSF School of Pharmacy News - Category: Universities & Medical Training Authors: Source Type: news